8-K: Liminatus Pharma Receives Nasdaq Delisting Notice

Liminatus Pharma, Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1 bid price rule, initiating a 180-day compliance period.

Summary

• Liminatus Pharma, Inc. (LIMN) received a notice from the Nasdaq Listing Qualifications Department on January 15, 2026, indicating non-compliance with Nasdaq Listing Rule 5450(a)(1).
• The non-compliance stems from the company's common stock failing to maintain a minimum bid price of $1 per share for the last 30 consecutive business days.
• This notification has no immediate effect on the listing of the company's common stock, which will continue to trade on Nasdaq under the symbol LIMN.
• The company has been granted a compliance period of 180 calendar days, until July 14, 2026, to regain compliance with the Bid Price Rule.
• To regain compliance, the closing bid price of the company's security must be at least $1 for a minimum of ten consecutive business days.
• If the company chooses to implement a reverse stock split, it must be completed no later than ten business days prior to the expiration date of the compliance period.
• The company may be eligible for additional time to regain compliance if it does not do so during the initial 180-day period.
• Management is working diligently to regain compliance, but there is no assurance that the company will succeed within the prescribed timeframe.

Sentiment

Score: 3

Explanation: The filing indicates a significant negative event (Nasdaq non-compliance) which could lead to delisting, despite management's stated efforts to regain compliance and the temporary nature of the notice. This situation introduces substantial uncertainty and risk for investors.

Positives

• The notification has no immediate effect on the listing of the company's common stock, allowing it to continue trading on Nasdaq.
• The company has a 180-day compliance period, providing a window to address the minimum bid price deficiency.
• There is a possibility for the company to be eligible for additional time to regain compliance if needed.

Negatives

• The company is currently non-compliant with Nasdaq's minimum bid price rule, indicating sustained low stock performance.
• There is no assurance that the company will be able to regain compliance within the prescribed time period.
• The potential necessity of a reverse stock split, which can sometimes be perceived negatively by investors and may not guarantee long-term compliance.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price rule could ultimately lead to the delisting of the company's common stock.
• There is no assurance that the company will be able to maintain a closing bid price of at least $1 for ten consecutive business days.
• Nasdaq may not accept the company's plan to regain compliance, or the company may not meet continued listing standards in the future.
• Actual actions or events could differ materially from forward-looking statements due to various risks, uncertainties, and assumptions.

Future Outlook

The company is working diligently to regain compliance with Nasdaq's listing rules, but there is no assurance that it will be able to do so within the prescribed time period or that Nasdaq will accept its plan. The company undertakes no obligation to publicly update forward-looking statements unless required by law.

Management Comments

• "The Company is working diligently to regain compliance with Nasdaq's listing rules."

Industry Context

This notice is a standard regulatory action for companies whose stock price falls below Nasdaq's minimum bid requirements, common across various industries, including biotechnology, where early-stage companies may experience significant stock price volatility.

Stakeholder Impact

• Shareholders: Face potential dilution if a reverse stock split is implemented, risk of delisting leading to reduced liquidity and market visibility, and uncertainty regarding the company's future on Nasdaq.
• Employees: Potential impact on the value of stock-based compensation and overall company stability perception due to listing uncertainty.

Next Steps

• Regain compliance with Nasdaq's Bid Price Rule by achieving a closing bid price of at least $1 for ten consecutive business days.
• Potentially implement a reverse stock split no later than ten business days prior to the compliance period expiration if other methods are insufficient.
• Continue to monitor and address all Nasdaq listing standards to maintain its public listing.

Key Dates

Recommendation

The company has received a delisting notice from Nasdaq due to its stock trading below the minimum bid price, indicating fundamental market weakness. While a compliance period exists, the uncertainty of regaining compliance, potentially through a reverse stock split which often signals underlying issues, presents significant risk. Investors should consider selling to mitigate further potential losses and reduced liquidity if delisting occurs.

Keywords

Liminatus Pharma, LIMN, Nasdaq, Delisting Notice, Bid Price Rule, Compliance Period, Reverse Stock Split, SEC Filing, 8-K, Biotechnology, Pharmaceuticals